10 patients defined as ‘nonprogressing’ and 10 ‘progressing’ based on the change of PSA level over the 5 years of monitoring), metastatic PC (n = 5), and BPH (n = 5) [80]. This evidence concerns the gene PROS1 and pachyonychia congenita.